# Elekta B

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/elektab).

## Overview

Elekta is a global leader in radiotherapy solutions, specializing in advanced technologies to treat cancer and neurological diseases. The company is renowned for its innovative products like the Elekta Evo linear accelerator and the Elekta ONE software suite, which enhance treatment efficiency and patient outcomes. Elekta's offerings are supported by AI-driven services and a robust global network, making it a key player in the radiotherapy market. Headquartered in Stockholm, Sweden, Elekta operates across multiple regions, contributing to its strong market presence and financial performance.

## Products & services

• Elekta Evo linear accelerator
• Elekta ONE software suite
• AI-supported radiotherapy services
• Advanced radiotherapy solutions
• Specialty radiotherapy products

- **Linear Accelerators** (40%) — Includes Elekta Evo and other advanced radiotherapy equipment.
- **Software Solutions** (30%) — Comprises Elekta ONE and other software for treatment planning and management.
- **AI-supported Services** (15%) — AI-driven services to enhance treatment efficiency.
- **Specialty Products** (15%) — Includes niche radiotherapy products for specific treatments.

- Elekta Evo linear accelerator
- Elekta ONE software suite
- AI-supported radiotherapy services
- Advanced radiotherapy solutions
- Specialty radiotherapy products

## Customers

Elekta serves a diverse range of customers primarily in the healthcare sector, including hospitals, cancer treatment centers, and clinics worldwide. These customers rely on Elekta's advanced radiotherapy solutions to improve patient outcomes and operational efficiency. The company's products are particularly valued for their innovative technology and ability to integrate with existing healthcare systems. Elekta's AI-supported services further enhance the appeal to customers seeking cutting-edge treatment solutions. The company's strong presence in both developed and emerging markets allows it to cater to a wide array of healthcare providers.

- **Hospitals** (primary) — Purchase advanced radiotherapy equipment to enhance treatment capabilities.
- **Cancer Treatment Centers** (primary) — Utilize Elekta's solutions for improved patient outcomes.
- **Clinics** (secondary) — Adopt AI-supported services for operational efficiency.

- Hospitals seeking advanced radiotherapy solutions
- Cancer treatment centers focusing on patient outcomes
- Clinics integrating AI-driven services for efficiency
- Healthcare providers in developed and emerging markets

## Geography

Elekta operates globally with significant market presence in the Americas, EMEA, and APAC regions. The company has a strong foothold in Europe, which is a key market for its innovative product launches. In APAC, Elekta experiences growth across most markets, although the Chinese market remains challenging. The Americas, particularly the U.S., have shown weaker sales, impacted by market conditions and regulatory factors. Elekta's global operations are supported by strategic manufacturing and supply centers that manage currency exposure and cost efficiencies.

- **EMEA** (40%) — Strong performance driven by new product launches
- **APAC** (34%) — Growth across most markets
- **Americas** (26%) — Weaker sales in the U.S.

- Strong market presence in Europe with new product launches
- Growth in APAC markets despite challenges in China
- Weaker sales in the U.S. due to market conditions
- Strategic manufacturing and supply centers manage currency exposure

## Strategy

Elekta's strategic priorities focus on expanding its software offerings and enhancing its product portfolio with innovative solutions like the Elekta Evo. The company aims to leverage AI and digital technologies to improve treatment efficiency and patient outcomes. Elekta is also committed to maintaining strong financial performance through price increases and cost management. The company is actively exploring partnerships and collaborations to expand its global reach and market share. These strategic initiatives are designed to position Elekta as a leader in the radiotherapy market, driving long-term growth and competitiveness.

- **Expand software offerings** (medium-term) — To enhance treatment planning and management capabilities.
- **Leverage AI technologies** (long-term) — To improve treatment efficiency and outcomes.
- **Global market expansion** (long-term) — To increase market share and reach new customers.

- Expand software offerings with Elekta ONE
- Enhance product portfolio with innovations like Elekta Evo
- Leverage AI and digital technologies for efficiency
- Maintain financial performance through price increases
- Explore partnerships for global expansion

## Risks

Elekta faces several risks, including geopolitical tensions that may affect its operations and partnerships in certain markets. Currency fluctuations and economic uncertainties in key regions like the U.S. and China pose additional challenges. The company is also exposed to regulatory risks, particularly in the U.S., where product approvals can impact sales. Industry-specific risks include technological advancements by competitors and changes in healthcare regulations. Elekta's financial performance is sensitive to these factors, which could affect its revenue and profitability.

- **Geopolitical tensions** [high] — May impact local partnering and sales.
- **Currency fluctuations** [medium] — Affect financial performance and cost management.
- **Regulatory risks** [high] — Impact product approvals and sales in the U.S.

- Geopolitical tensions impacting operations and partnerships
- Currency fluctuations affecting financial performance
- Regulatory risks in the U.S. impacting product approvals
- Technological advancements by competitors
- Changes in healthcare regulations

## Accounting

Elekta's financial statements are influenced by significant quarterly variations in volumes and product mix, impacting net sales and profits. Revenue recognition is critical, with solutions recognized at a point in time and services over time. The company has faced non-cash impairments due to discontinued R&D projects, affecting intangible asset valuations. Currency exposure is concentrated in product supply centers, which can lead to exchange differences reported in global costs. These accounting matters require careful analysis to understand Elekta's financial performance and position.

- **Revenue recognition** — critical
- **Intangible asset impairment** — high

- Quarterly variations in volumes and product mix affect net sales
- Revenue recognition: solutions at a point in time, services over time
- Non-cash impairments from discontinued R&D projects
- Currency exposure concentrated in product supply centers

---

*Last updated: 2026-08-11T04:04:51.923993+00:00*